Bavarian Nordic names Tarja Stenvall as its next CEO

Tarja Stenvall will become Chief Executive Officer of Bavarian Nordic on October 15, succeeding Paul Chaplin after roughly 12 years in the role. Bavarian Nordic’s announcement sets the date, while STAT News describes the leadership reset following Chaplin’s planned departure.\n\nStenvall joins from Sanofi, where she was senior vice president and head of global franchises for diabetes and cardiovascular diseases. Her brief at Bavarian Nordic is to expand the global impact of its vaccines, strengthen the company’s position as a vaccine leader and translate scientific innovation into patient impact and sustainable growth.\n\nFrom portfolio strategy to vaccine leadership\n\nThe appointment gives Bavarian Nordic a leader whose recent work combined portfolio strategy with long-term planning for a large global franchise. She has also held leadership roles across general medicines, Europe and Latin America, and served as vice president for vaccines at Sanofi.\n\nStenvall will take over a company whose chair, Anne Louise Eberhard, said it intends to keep scaling its platform for infectious disease and public-health resilience. The move adds another chapter to a healthcare leadership cycle that also includes Legend Biotech’s appointment of Ingrid Zhang.